Zogenix Stock Forecast, Price & News

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zogenix in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Zogenix stock.
View analyst ratings for Zogenix or view top-rated stocks.

Wall Street analysts have given Zogenix a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Zogenix wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Zogenix is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Zogenix.

Zogenix, Inc. (NASDAQ:ZGNX) issued its quarterly earnings data on Thursday, May, 6th. The company reported ($1.00) EPS for the quarter, missing the consensus estimate of ($0.98) by $0.02. The business earned $13.68 million during the quarter, compared to analyst estimates of $12.34 million. Zogenix had a negative trailing twelve-month return on equity of 60.93% and a negative net margin of 917.30%. The firm's revenue was up 995.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.54) earnings per share.
View Zogenix's earnings history.

Zogenix's stock was trading at $22.69 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ZGNX stock has decreased by 21.6% and is now trading at $17.79.
View which stocks have been most impacted by COVID-19.

5 Wall Street analysts have issued 12-month price objectives for Zogenix's shares. Their forecasts range from $48.00 to $65.00. On average, they anticipate Zogenix's share price to reach $59.00 in the next twelve months. This suggests a possible upside of 231.6% from the stock's current price.
View analysts' price targets for Zogenix or view top-rated stocks among Wall Street analysts.

7 employees have rated Zogenix CEO Stephen Farr, Ph.D. on Glassdoor.com. Stephen Farr, Ph.D. has an approval rating of 85% among Zogenix's employees.

Some companies that are related to Zogenix include Johnson & Johnson (JNJ), Pfizer (PFE), Eli Lilly and (LLY), AbbVie (ABBV), Merck & Co., Inc. (MRK), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics Public (HZNP), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Nektar Therapeutics (NKTR), Corcept Therapeutics (CORT), Pacira BioSciences (PCRX) and Supernus Pharmaceuticals (SUPN).
View all of ZGNX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Zogenix investors own include GW Pharmaceuticals (GWPH), Gilead Sciences (GILD), Vanda Pharmaceuticals (VNDA), AbbVie (ABBV), QUALCOMM (QCOM), Advanced Micro Devices (AMD), (CGC), Sorrento Therapeutics (SRNE), Southwest Airlines (LUV) and Micron Technology (MU).

Zogenix trades on the NASDAQ under the ticker symbol "ZGNX."

Zogenix's stock is owned by many different institutional and retail investors. Top institutional shareholders include RA Capital Management L.P. (9.47%), BlackRock Inc. (8.82%), Morgan Stanley (6.71%), Franklin Resources Inc. (4.86%), Bank of New York Mellon Corp (4.31%) and Janus Henderson Group PLC (3.19%). Company insiders that own Zogenix stock include Ashish M Sagrolikar, Cam L Garner, Gail M Farfel, James B Breitmeyer, Mark C Wiggins, Michael P Smith, Renee P Tannenbaum and Stephen J Farr.
View institutional ownership trends for Zogenix.

ZGNX stock was sold by a variety of institutional investors in the last quarter, including Vivo Capital LLC, D. E. Shaw & Co. Inc., Millennium Management LLC, Woodline Partners LP, SG Americas Securities LLC, Voloridge Investment Management LLC, 683 Capital Management LLC, and Eversept Partners LP.
View insider buying and selling activity for Zogenix or view top insider-selling stocks.

ZGNX stock was bought by a variety of institutional investors in the last quarter, including Artisan Partners Limited Partnership, Bridger Management LLC, Franklin Resources Inc., Assenagon Asset Management S.A., Morgan Stanley, Bank of New York Mellon Corp, BlackRock Inc., and Healthcare of Ontario Pension Plan Trust Fund. Company insiders that have bought Zogenix stock in the last two years include Ashish M Sagrolikar, Cam L Garner, Mark C Wiggins, and Renee P Tannenbaum.
View insider buying and selling activity for Zogenix or or view top insider-buying stocks.

Shares of ZGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ZGNX stock can currently be purchased for approximately $17.79.

Zogenix has a market capitalization of $992.91 million and generates $13.64 million in revenue each year. The company earns $-209,380,000.00 in net income (profit) each year or ($3.88) on an earnings per share basis.

Zogenix employs 218 workers across the globe.

The official website for Zogenix is www.zogenix.com.

Zogenix is headquartered at 5959 Horton Street Suite 500, EMERYVILLE CA, 94608.

Zogenix's mailing address is 5959 Horton Street Suite 500, EMERYVILLE CA, 94608. The company can be reached via phone at 510-550-8300 or via email at [email protected]